Company Overview and News

Alta Zinc receives $3 million to advance Gorno Zinc Project

Alta Zinc Ltd (ASX:AZI) has completed its share placement raising $3 million through the issue of 272.7 million shares priced at 1.1 cents.

Alta Zinc identifies new large zone of mineralisation at Gorno Zinc Project in Italy

Alta Zinc Ltd (ASX:AZI) has released assay results from an underground channel sampling program targeting a new zone at its Gorno Zinc Project in northern Italy.

Alta Zinc targets high-grade zones in 2018 as it looks to grow resource

Alta Zinc Ltd (ASX:AZI), operator of the Gorno Zinc Project in Italy, officially became the trading name of previously ASX listed entity Energia Minerals (formerly ASX:EMX) on December 4, 2017.

Energia Minerals begins trading as Alta Zinc after rebranding

Alta Zinc Limited (ASX:AZI) managing director Alexander Burns speaks to Proactive following the miner's name change from Energia Minerals (ASX:EMX).

Energia Minerals confirms further potential for its zinc project in Italy

Energia Minerals Ltd (ASX:EMX) ) has received positive assay results from the recently completed underground grab sampling program at its Gorno Zinc Project in northern Italy.

The zinc price is on the rise, but which companies are set to benefit the most?

Balkan Zinc looks set to be the first zinc miner to list in London - if not quite in living memory, then at least in a long, long while.

Energia raises $6m for zinc project

Local explorer Energia Minerals has tapped investors for $6.1 million to fund ongoing work at its Gorno zinc project in Italy.

Scoping study results boost Caravel shares

Caravel Minerals believes its Calingiri copper mine is set to be an outstanding project, based on a detailed scoping study that it believes is a best-case example of what listed companies need to prepare in order to meet current disclosure rules.

Caravel jumps on scoping study results

Caravel Minerals believes its Calingiri copper mine is set to be an outstanding project, based on a detailed scoping study that it believes is a best-case example of what listed companies need to prepare in order to meet current disclosure rules.

Energia Minerals Ltd to update on study for Gorno zinc

Energia Minerals Ltd (ASX:EMX) has been granted a trading halt by the ASX this morning, pending an update on the completion of a Scoping Study at the Gorno Zinc Project. The wholly-owned project is located in northern Italy. The halt will last until the opening of trade on Thursday 21st April 2016, or earlier if an announcement is made to the market.

Trading Halt


Energia Minerals Ltd estimates mineral bounty at Gorno Zinc Project

Energia Minerals Limited has reported indicated and inferred resources of zinc, lead and silver at the Colonna Zorzone Zinc Deposit within its 100%-owned Gorno Zinc Project in Northern Italy

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...